Pfizer and BioNTech, the manufacturers of one of the three authorized Covid-19 vaccines in the U.S., plan to file for full approval from the Food and Drug Administration by the end of May as they expect the vaccine to generate about $26 billion in revenue this year.
- Pfizer and German drug manufacturer BioNTech announced their plan to ask the FDA for full approval of its vaccine in its quarterly earnings report.
- The vaccine, the first Covid-19 jab to be authorized for emergency use in the U.S., was given its emergency use authorization in December, and is currently authorized to be administered to Americans over the age of 16.
- The vaccine brought it $3.5 billion in revenue in the first three months of 2021.
- The FDA is expected to expand eligibility for the Pfizer vaccine to adolescents between the ages of 12 and 15 as soon as this week.
Read the full article at: Forbes